Donate Now Help support this project

References

What are the origins of the program SeeMyRisk.com?

SeeMyRisk.com was the idea and invention of Professor John Boyages. Working with two other inventors, Professor Richard Taylor and Dr Nathan Coombs, the idea became a reality. The Vitamin D calculator has been developed by Kellie Bilinski and John Boyages with review by Richard Taylor and Nathan Coombs.

This group has subsequently published numerous papers related to this complex area, including

  • Coombs N, Taylor R, Wilcken N, Boyages J. Hormone Replacement therapy and breast cancer: estimate of risk. British Medical Journal 2005; 331 347-49.
  • Coombs N, Taylor R, Wilcken N, Boyages J. HRT and breast cancer: Impact on population risk and incidence. European Journal of Cancer. 41:1775-1781. 2005.
  • Coombs N, Taylor R, Wilcken N, Fiorica J, Boyages J. Hormone replacement therapy and breast cancer risk in California. Breast Journal. 11(6):410-5, 2005.
  • Taylor R, Boyages J. Estimating risk of breast cancer from population incidence affected by widespread mammographic screening. Journal of Medical Screening. 1:8, 73-76. 2001.
  • Taylor R and Boyages J. Absolute risk of breast cancer for Australian women with a family history. Australia and New Zealand Journal of Surgery 2000; 70: 725-31.

Key References for HRT Component of the SeeMyRisk breast cancer Calculator

  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
  • Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006; 295: 1647-57.
  • Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419-27.
  • Collins JA, Blake JM, Crosignani PG. Breast Cancer risk with postmenopausal hormone treatment. Human Repro Update 2005; 11: 545-60.
  • Chlebowski RT, Hendrix SL, Langer RD et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289: 3243-53.
  • Anderson GL, Limacher M, Assaf AR, Bassford T. The effects of conjugated equine estrogn in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA. 2004; 291; 1701-12.
  • Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419-27.
  • Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002; 360: 942-4.

Key References for Family History Component of the SeeMyRisk breast cancer Calculator

The data for the family history component of the program come from:

  • Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 358(9291):1389-99, 2001 Oct
  • Pharoah P, Day N, Duffy S, Easton D, Ponder B. Family history and the risk of breast cancer: a systematic review and meta-analysis. International Journal of Cancer. 71, 800-809, 1997.

Key References for Family History Component of the SeeMyRisk prostate cancer Calculator

  • ChenY-C, Page, JH, Chen, R Giovannucci E. FamilyHistoryof Prostate and Breast Cancer and the Risk of Prostate Cancer in the PSA Era. The Prostate 68:1582-1591 (2008)
  • Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, Teh CZ, Stamey T.Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada.Am J Epidemiol. 1995 Apr 15;141(8):732-40.
  • Johns LE and Houslston RS. BJU Int. 2003 Jun;91(9):789-94. A systematic review and meta-analysis of familial prostate cancer risk.

Key References for SeeMyRisk of Vitamin D Deficiency Calculator

  • Stalgis-Bilinski KL, Boyages J, Salisbury EL, Dunstan CR, Henderson SI, Talbot PL. Burning daylight: balancing vitamin D requirements with sensible sun exposure. Med J Aust. 2011 Apr 4;194(7):345-8.
  • Holick MF. Vitamin D: a D-Lightful health perspective. Nutr Rev 2008 Oct;66(10 Suppl 2):S182-S194
  • Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. Calcified Tissue International 1988 Oct;43(4):199-201.
  • Compston JE, Vedi S, Ledger JE, Webb A, Gazet JC, Pilkington TR. Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr 1981 Nov;34(11):2359-63.
  • FoodWorks 2009, Xyris Software, Australia PTY, LTD.
  • Non-ionising Radiation Branch, Australian Radiation Protection and Nuclear Safety Agency (ARPANSA).